

# Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C5914D501FF4EN.html>

Date: March 2022

Pages: 84

Price: US\$ 2,000.00 (Single User License)

ID: C5914D501FF4EN

## Abstracts

Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 2, 7, 1, 8, 3 and 2 respectively.

Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Toxicology).

The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Toxicology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Nausea and Vomiting - Overview

Chemotherapy Induced Nausea and Vomiting - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development

Acacia Pharma Ltd

AcuCort AB

Amzell BV

Aphios Corp

Arovella Therapeutics Ltd

Athenex Inc

Axim Biotechnologies Inc

Benuvia Therapeutics Inc

Bionorica SE

Camurus AB

Daewoong Pharmaceutical Co Ltd

Ethicann Pharmaceuticals Inc

Helsinn Group

Hoverink Biotechnologies Inc

IntelGenx Corp

Jiangsu Hengrui Medicine Co Ltd

LipoSeuticals Inc

LP Pharmaceutical (Xiamen) Co Ltd

Luxena Pharmaceuticals Inc

MannKind Corp

Senzer Ltd

Shackelford Pharma Inc

Skye Bioscience Inc

SoluBest Ltd

Starton Therapeutics Inc

Yichang Humanwell Pharmaceutical Co Ltd

Chemotherapy Induced Nausea and Vomiting - Drug Profiles

(fosnetupitant chloride hydrochloride + palonosetron hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(netupitant + palonosetron hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

History of Events

AMZ-004 - Drug Profile

Product Description

Mechanism Of Action

APD-403 - Drug Profile

Product Description

Mechanism Of Action

History of Events

aprepitant - Drug Profile

Product Description

Mechanism Of Action

aprepitant - Drug Profile

Product Description

Mechanism Of Action

aprepitant - Drug Profile

Product Description

Mechanism Of Action

dexamethasone - Drug Profile

Product Description

Mechanism Of Action

History of Events

dronabinol - Drug Profile

Product Description

Mechanism Of Action

History of Events

dronabinol - Drug Profile

Product Description

Mechanism Of Action

History of Events  
dronabinol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
dronabinol - Drug Profile  
Product Description  
Mechanism Of Action  
dronabinol - Drug Profile  
Product Description  
Mechanism Of Action  
dronabinol - Drug Profile  
Product Description  
Mechanism Of Action  
dronabinol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
fosnetupitant chloride hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
frovatriptan dimeglumine - Drug Profile  
Product Description  
Mechanism Of Action  
granisetron - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
granisetron - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
HR-20013 - Drug Profile  
Product Description  
Mechanism Of Action  
LPI-1504 - Drug Profile  
Product Description  
Mechanism Of Action

LPI-1505 - Drug Profile

Product Description

Mechanism Of Action

NB-1222 - Drug Profile

Product Description

Mechanism Of Action

History of Events

olanzapine - Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron - Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

palonosetron - Drug Profile

Product Description

Mechanism Of Action

palonosetron hydrochloride LA - Drug Profile

Product Description

Mechanism Of Action

History of Events

SPID-301 - Drug Profile

Product Description

Mechanism Of Action

Zindol - Drug Profile

Product Description

Mechanism Of Action

History of Events

Chemotherapy Induced Nausea and Vomiting - Dormant Projects

Chemotherapy Induced Nausea and Vomiting - Discontinued Products



## Chemotherapy Induced Nausea and Vomiting - Product Development Milestones Featured News & Press Releases

Mar 01, 2022: AcuCort is exempted from the application fee by the U.S. Food and Drug Administration

Feb 22, 2022: AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT

Feb 17, 2022: AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT

Dec 02, 2021: Helsinn announces European Commission approval of the liquid formulation of AKYNZEO (fosnetupitant/palonosetron)

Nov 30, 2021: ESMO: Fosnetupitant is valuable in the prophylaxis of acute, delayed, and beyond delayed cinv

Oct 05, 2021: AcuCort's drug ISICORT demonstrates a three-year shelf life

Oct 05, 2021: REDUVO- A major milestone for Tetra Bio-Pharma

Sep 03, 2021: AcuCort receives a second US patent protection for its drug ISICORT

Jun 16, 2021: Starton Therapeutics phase 2 TROPIC-I clinical study will be first to use total control primary endpoint in superiority study

Jun 02, 2021: Health Canada accepts new drug submission for REDUVO as a treatment for patients with chemotherapy-induced nausea and vomiting

May 05, 2021: DanCann Pharma have signed a definitive distribution agreement with Tetra Bio-Pharma for the exclusive distribution of Reduvo Adversa and Qixleaf in Scandinavia and Germany

May 03, 2021: Tetra Bio-Pharma granted a drug establishment license to distribute REDUVO soft gel capsules in Canada

Apr 26, 2021: AcuCort progresses into a new phase and strengthens the commercialization team

Apr 14, 2021: Tetra Bio-Pharma provides update on its New Drug Submission application in Canada

Apr 13, 2021: Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by AcuCort AB, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Amzell BV, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Arovella Therapeutics Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Athenex Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Axim Biotechnologies Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Benuvia Therapeutics Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Bionorica SE, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Ethicann Pharmaceuticals Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Group, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Hoverink Biotechnologies Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by IntelGenx Corp, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by LipoSeuticals Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by LP Pharmaceutical

(Xiamen) Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Luxena Pharmaceuticals Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Senzer Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Shackelford Pharma Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Skye Bioscience Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Starton Therapeutics Inc, 2022

Chemotherapy Induced Nausea and Vomiting - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, 2022

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, 2022 (Contd..1)

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, 2022 (Contd..2)

Chemotherapy Induced Nausea and Vomiting - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Chemotherapy Induced Nausea and Vomiting Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C5914D501FF4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5914D501FF4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

